Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.18 EX-10.18
- 10.19 EX-10.19
- 10.20 EX-10.20
- 10.21 EX-10.21
- 10.22 EX-10.22
- 10.23 EX-10.23
- 10.24 EX-10.24
- 10.25 EX-10.25
- 10.26 EX-10.26
- 10.27 EX-10.27
- 10.29 EX-10.29
- 21.1 EX-21.1
- 23.2 EX-23.2
- 23.3 EX-23.3
- Download Excel data file
- View Excel data file
Associated filings
- 17 Jun 21 EFFECT Notice of effectiveness
- 16 Jun 21 424B3 Prospectus supplement
- 14 Jun 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 9 Jun 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 3 May 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 21 Apr 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 19 Apr 21 S-4/A Registration of securities issued in business combination transactions (amended)
- 16 Apr 21 S-4/A Registration of securities issued in business combination transactions (amended)
-
15 Mar 21 S-4 Registration of securities issued in business combination transactions
ENSC similar filings
- 21 Apr 21 Registration of securities issued in business combination transactions (amended)
- 19 Apr 21 Registration of securities issued in business combination transactions (amended)
- 16 Apr 21 Registration of securities issued in business combination transactions (amended)
- 15 Mar 21 Registration of securities issued in business combination transactions
Filing view
External links
Exhibit 23.3
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the inclusion in this Registration Statement on Form S-4 and related joint proxy statement/prospectus of our report dated March 15, 2021, with respect to the consolidated financial statements of Ensysce Biosciences, Inc. as of December 31, 2020 and 2019 and for the years then ended (which report includes an explanatory paragraph regarding the existence of substantial doubt about the Company’s ability to continue as a going concern), and to the reference to us under the heading “Experts” in the joint proxy statement/prospectus which is part of this Registration Statement.
/s/ Mayer Hoffman McCann P.C.
San Diego, California
March 15, 2021